21 CFR Part 1271 · Human Cells, Tissues, and Cellular and Tissue-Based Products

§ 1271.47 What procedures must I establish and maintain?

Subpart C - Donor Eligibility Official text on eCFR Amendment history

(a) General. You must establish and maintain procedures for all steps that you perform in testing, screening, determining donor eligibility, and complying with all other requirements of this subpart. Establish and maintain means define, document (in writing or electronically), and implement; then follow, review, and as needed, revise on an ongoing basis. You must design these procedures to ensure compliance with the requirements of this subpart.

(b) Review and approval. Before implementation, a responsible person must review and approve all procedures.

(c) Availability. Procedures must be readily available to the personnel in the area where the operations to which they relate are performed, or in a nearby area if such availability is impractical.

(d) Departures from procedures. You must record and justify any departure from a procedure relevant to preventing risks of communicable disease transmission at the time of its occurrence. You must not make available for distribution any HCT/P from a donor whose eligibility is determined under such a departure unless a responsible person has determined that the departure does not increase the risks of communicable disease transmission through the use of the HCT/P.

(e) Standard procedures. You may adopt current standard procedures, such as those in a technical manual prepared by another organization, provided that you have verified that the procedures are consistent with and at least as stringent as the requirements of this part and appropriate for your operations.

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

What FDA inspectors cite under § 1271.47

Form FDA 483 observations citing this section, fiscal years 2009–2026 (Human Tissue for Transplantation).

  • Testing, screening, donor eligibility procedures 275
  • Procedures for all other requirements 188
  • Design of procedures to ensure compliance 73
  • Review and approval of procedures 41
  • Departures: recording and justifying 13
  • Availability of procedures 9

Warning letters citing § 1271.47

24 FDA warning letters since 2017 cite this section ; the most recent:

FDA guidance that cites § 1271.47

Amendment history

Federal Register documents that created or amended this section.